First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

Although chimeric antigen receptor (CAR) T cell therapy has revolutionized type B cancer treatment, efficacy remains limited in various lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy but also increase safety concerns. Several strategi...

Full description

Saved in:
Bibliographic Details
Main Authors: Pedro Justicia-Lirio, María Tristán-Manzano, Noelia Maldonado-Pérez, Carmen Barbero-Jiménez, Marina Cortijo-Gutiérrez, Kristina Pavlovic, Francisco J. Molina-Estevez, Pilar Muñoz, Ana Hinckley-Boned, Juan R. Rodriguez-Madoz, Felipe Prosper, Carmen Griñán-Lison, Saúl A. Navarro-Marchal, Carla Panisello, Julia Muñoz-Ballester, Pedro A. González-Sierra, Concha Herrera, Juan A. Marchal, Francisco Martín
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
MT: Delivery Strategies
CAR-T cells
TRUCKs
Lent-On-Plus
lentiviral vectors
regulation
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253124001951
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items